Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 04, 2016
- Data published in the Proceedings of National Academy of Sciences (PNAS) -
- Results show ataluren targets the protein production machinery -
Additional Formats
Sep 12, 2016
SOUTH PLAINFIELD, N.J. , Sept. 12, 2016 /PRNewswire/ -- PTC Therapeutics , Inc. ( NASDAQ : PTCT) today announced that on September 8, 2016 it approved non-statutory stock options to purchase an aggregate of 22,900 shares of its common stock to eleven new employees.
Additional Formats
Sep 07, 2016
- STRIVE Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community -
- PTC's Disease Awareness Website - www.DuchenneAndYou.com now available in multiple languages -
Additional Formats
Aug 04, 2016
-- Translarna™ net sales of $15.4M representing 150% year-over-year growth --
-- Full-year Translarna net sales on-track to meet guidance of $65M to $85M --
-- NHS England and NICE agreement completed allowing reimbursed access --
-- EMA review of European marketing authorization for Translarna continues --
-- FDA appeal process initiated in the U.S. --
Additional Formats
Jul 25, 2016
SOUTH PLAINFIELD, N.J. , July 25, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced global regulatory updates on Translarna ™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) and nonsense mutation cystic fibrosis (nmCF).
Additional Formats
Jul 21, 2016
SOUTH PLAINFIELD, N.J. , July 21, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Thursday, August 4, 2016
Additional Formats
Jul 07, 2016
--Important decision allows reimbursed access to Translarna, the first approved therapy to treat the underlying cause of Duchenne muscular dystrophy--
Additional Formats
Jun 13, 2016
SOUTH PLAINFIELD, N.J. , June 13, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe / Canada region from 2009 to 2011 and as President
Additional Formats
Jun 10, 2016
SOUTH PLAINFIELD, N.J. , June 10, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week 009 trial of Translarna™ (ataluren) for the treatment of nonsense mutation cystic fibrosis
Additional Formats
May 16, 2016
STRIVE Awards Program Recognizes Excellence and Innovation in the Cystic Fibrosis Community
Additional Formats